You are here

ACOUSTOPHORETIC TRANSFUSION TO REDUCE EMBOLIZATION IN CARDIOPULMONARY BYPASS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL118833-01A1
Agency Tracking Number: R43HL118833
Amount: $157,332.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
380 MAIN ST
WILBRAHAM, MA 01095-1639
United States
DUNS: 962516147
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 LOUIS MASI
 (413) 596-5900
 l.masi@fdsonics.com
Business Contact
 LOUIS MASI
Phone: (413) 596-5900
Email: l.masi@fdsonics.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Retransfusion of a patient's shed blood during cardiopulmonary bypass is attractive since it reduces the need for allogeneic transfusion, minimizes cost, and decreases transfusion related morbidity. Heterologous transfusions are linked to increased long term mortality after cardiac surgery. However, brain damage after cardiac surgery with retransfusion of shed blood is a significant cause of morbidity, including post-operative, short-term and long-term cognitive dysfunction, and mortality. Among the preoperative and postoperative factors that have a significant correlation with stroke are diabetes, hypertension, and recent myocardial infarction. It is well-documented that these factors are more prevalent in minorities. Evidence suggests that lipid microembolisms associated with the retransfusion of the shed blood are the predominant causes of the neurocognitive disorders. Traditional techniques to remove the lipids from the shed blood include screens and centrifugatio

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government